NCT05463796View on ClinicalTrials.gov

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

RecruitingOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

March 25, 2027

Study Completion Date

March 25, 2032

Conditions
Cancer RiskCancer Predisposition SyndromeHereditary Cancer PredictionChildhood Cancer SurvivorsAdult Cancer SurvivorsIARC CarcinogensSmoking HistoryLung CancerDuctal/Lobular CarcinomaBarrett EsophagusPancreatic Precursor LesionsColonic Dysplasia/AdenomataNon-Alcoholic Fatty Liver DiseaseNon Alcoholic SteatohepatitisCirrhosisHigh Grade Prostatic Epithelial NeoplasiaHigh-grade Bladder Urothelial Dysplasia/Carcinoma in SituAdenomatous HyperplasiaHigh-risk Oral Precancerous DiseasesMelanocytic Lesion, AdultHematologic MalignancyLung; NodeSerous Tubal Intraepithelial CarcinomaEndometrial Intraepithelial NeoplasiaCervical and Endocervical Carcinoma in SituVulvar Intraepithelial NeoplasiaNephrogenic RestsBenign Bone Lesions With Risk of Malignant DegenerationGiant Cell TumorOsteochondromaSpitz Nevus
Interventions
OTHER

Samples

"Tissue samples will be collected during a routine visit. Participants will be asked to donate any of the following tissue types:~Blood, Buccal swab (saliva) or mouthwash, Urine, Stool, Biopsy or surgical tissue (i.e., bone marrow),Bodily fluids, Other tissues"

Trial Locations (1)

02115

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER